title: Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study.
abstract: BACKGROUND
  Hepatocarcinoma is one of the most common malignant tumours world-wide with poor prognosis. Treatment of locally advanced hepatocarcinoma is still controversial. Transcatheter arterial (chemo-)embolisation of hepatocarcinoma are widely used methods but some aspects regarding their use and usefulness have not yet been clarified. Systemic remedies have not yet been proven to affect patient survival.
  
  
  OBJECTIVE
  To determine if intra-arterial chemotherapy with 5-flurouracil and folinic acid in locally advanced hepatocarcinoma is a viable alternative to existing therapies.
  
  
  METHODS
  Twenty-four inoperable consecutive patients with locally advanced hepatocarcinoma were enrolled. They all underwent intra-arterial chemotherapy via a surgically implanted port-a-cath, and folinic acid (100 mg/m2) and 5-flurouracil (up to 550 mg/m2) were administered with a 1-week or a 2-week schedule.
  
  
  RESULTS
  Nineteen patients completed the study: 2 showed a complete positive response, 11 a partial response, 6 stable disease, while 4 showed a disease progression. Median survival time was 19 (range 4-85) months. Child A patients showed a significant longer survival.
  
  
  CONCLUSIONS
  Intra-arterial chemotherapy using folinic acid and 5-flurouracil may be useful in the treatment of locally advanced hepatocarcinoma in cirrhotic patients even in the presence of thrombosis. This treatment could be also useful in comparing transarterial chemoembolisation to a curative treatment.
authors.affiliation: Section of Medical Oncology, Department of Internal Medicine, School of Medicine, University of Florence, Viale G. B. Morgagni, 85, I-50134 Florence, Italy. r.mazzanti@dmi.unifi.it
authors.forename: R
authors.initials: R
authors.lastname: Mazzanti
authors.forename: A L
authors.initials: AL
authors.lastname: Giallombardo
authors.forename: E
authors.initials: E
authors.lastname: Mini
authors.forename: S
authors.initials: S
authors.lastname: Nobili
authors.forename: B
authors.initials: B
authors.lastname: Neri
authors.forename: U
authors.initials: U
authors.lastname: Arena
authors.forename: P
authors.initials: P
authors.lastname: Pantaleo
authors.forename: V
authors.initials: V
authors.lastname: Fabbroni
authors.forename: M
authors.initials: M
authors.lastname: Ghilardi
authors.forename: R
authors.initials: R
authors.lastname: Gattai
authors.forename: L
authors.initials: L
authors.lastname: Bandettini
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007269:Injections, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D002955:Leucovorin; D005472:Fluorouracil